Severity of Newly Diagnosed Coronary Artery Disease in Patients With Newly Diagnosed Diabetes and Pre-diabetes: A Cohort Study in a Cardiac Center in Saudi Arabia

Saud Al Babtain Cardiac Center1 site in 1 country150 target enrollmentJuly 1, 2021

ConditionsCoronary Artery Disease Dysglycemia

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Coronary Artery Disease
Sponsor: Saud Al Babtain Cardiac Center
Enrollment: 150
Locations: 1
Primary Endpoint: Coronary artery disease severity
Status: Completed
Last Updated: 3 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This cohort study will measure how severe is the coronary artery disease (CAD), at time of CAD diagnosis, clinically and angiographically in the different cohorts of newly diagnosed diabetes and prediabetes versus normal glycemia patients in the study center.

Registry

clinicaltrials.gov

Start Date

July 1, 2021

End Date

September 30, 2022

Last Updated

3 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Saud Al Babtain Cardiac Center

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•All adult patients with consents.
•First time diagnosis of CAD and no prior diagnosis of diabetes milletus (DM), or prediabetes.
•Coronary artery disease confirmed by invasive coronary angiography.

Exclusion Criteria

•Patients with known significant anemia, increased hemoglobin turnover, active hemoglobin drops or on erythropoietin therapy.
•Pregnant and post-partum patients (up to 3 months post-delivery).
•Patients with severe chronic renal failure (estimated glomerular filtration rate (eGFR) \< 30 mL/min/1.72 m2).
•Patients on any medications with glucose lowering effects.

Outcomes

Primary Outcomes

Coronary artery disease severity

Time Frame: 1 day (During the hospital admission)

To measure how severe is the CAD, at time of CAD diagnosis, clinically and angiographically in the different cohorts of newly diagnosed diabetes and prediabetes versus normal glycemia patients.